Skip to main content
Premium Trial:

Request an Annual Quote

$67 Million in First Closing of New Burrill VC Fund

NEW YORK, Oct. 24-Burrill & Company today announced the closing of a new $67 million life sciences venture capital fund.


The San Francisco-based merchant bank, which operates six other life sciences funds, expects that the Burrill Life Sciences Capital Fund will eventually hit $250 million.


The fund will invest in early- to mid-stage biotech and life sciences companies. Average investment size will range from $3 million to $10 million.


CEO G. Steven Burrill said in a statement that he expects the fund to reach its projected $250 million total during the next several months. He also said that in this difficult economic climate, the closing "is a strong endorsement both for biotech and for the Burrill & Company investment team."


Burrill had initially expected the Life Sciences fund to reach a $100 million closing in the spring of 2001. Recently, another Burrill fund has had trouble meeting its money-raising goalson schedule.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.